Barinthus Biotherapeutics (NASDAQ:BRNS) Announces Earnings Results

Barinthus Biotherapeutics (NASDAQ:BRNS) issued its quarterly earnings results on Friday. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09, Zacks reports.

Barinthus Biotherapeutics Stock Down 10.1%

BRNS stock traded down $0.12 during midday trading on Friday, reaching $1.07. 116,960 shares of the company’s stock traded hands, compared to its average volume of 43,794. The company has a market cap of $43.57 million, a price-to-earnings ratio of -0.62 and a beta of -0.70. Barinthus Biotherapeutics has a 52 week low of $0.64 and a 52 week high of $2.92. The firm’s fifty day moving average price is $1.26 and its 200-day moving average price is $1.15.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. boosted its stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 192,461 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned about 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent SEC filing. Institutional investors own 25.20% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Barinthus Biotherapeutics in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.